211 related articles for article (PubMed ID: 24130685)
1. High-throughput screening (HTS) and hit validation to identify small molecule inhibitors with activity against NS3/4A proteases from multiple hepatitis C virus genotypes.
Lee H; Zhu T; Patel K; Zhang YY; Truong L; Hevener KE; Gatuz JL; Subramanya G; Jeong HY; Uprichard SL; Johnson ME
PLoS One; 2013; 8(10):e75144. PubMed ID: 24130685
[TBL] [Abstract][Full Text] [Related]
2. Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease.
Ren J; Ojeda I; Patel M; Johnson ME; Lee H
Bioorg Med Chem Lett; 2019 Aug; 29(16):2349-2353. PubMed ID: 31201062
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
[TBL] [Abstract][Full Text] [Related]
4.
Ng TI; Tripathi R; Reisch T; Lu L; Middleton T; Hopkins TA; Pithawalla R; Irvin M; Dekhtyar T; Krishnan P; Schnell G; Beyer J; McDaniel KF; Ma J; Wang G; Jiang LJ; Or YS; Kempf D; Pilot-Matias T; Collins C
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084747
[TBL] [Abstract][Full Text] [Related]
5. Identification of non-macrocyclic small molecule inhibitors against the NS3/4A serine protease of hepatitis C virus through in silico screening.
Chaudhuri R; Lee H; Truong L; Torres J; Patel K; Johnson ME
J Chem Inf Model; 2012 Aug; 52(8):2245-56. PubMed ID: 22697413
[TBL] [Abstract][Full Text] [Related]
6. Discovery of small molecule inhibitors against the NS3/4A serine protease of Hepatitis C virus genotype 3 via highthroughput virtual screening and in vitro evaluations.
Sakhor W; Teoh TC; Yusof R; Lim SK; Razif MFM
Trop Biomed; 2020 Sep; 37(3):609-625. PubMed ID: 33612776
[TBL] [Abstract][Full Text] [Related]
7. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).
Seiwert SD; Andrews SW; Jiang Y; Serebryany V; Tan H; Kossen K; Rajagopalan PT; Misialek S; Stevens SK; Stoycheva A; Hong J; Lim SR; Qin X; Rieger R; Condroski KR; Zhang H; Do MG; Lemieux C; Hingorani GP; Hartley DP; Josey JA; Pan L; Beigelman L; Blatt LM
Antimicrob Agents Chemother; 2008 Dec; 52(12):4432-41. PubMed ID: 18824605
[TBL] [Abstract][Full Text] [Related]
8. Establishment and application of high throughput screening model for hepatitis C virus NS3-4A protease inhibitors in vitro.
Jian-rui L; Yan-bin W; Shu-yi S; Hong-shan C; Jian-dong J; Zong-gen B
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Feb; 33(1):98-101. PubMed ID: 21375947
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches.
Ezat AA; Elshemey WM
Life Sci; 2019 Jan; 217():176-184. PubMed ID: 30528183
[TBL] [Abstract][Full Text] [Related]
10. Allosteric inhibitors of the NS3 protease from the hepatitis C virus.
Abian O; Vega S; Sancho J; Velazquez-Campoy A
PLoS One; 2013; 8(7):e69773. PubMed ID: 23936097
[TBL] [Abstract][Full Text] [Related]
11. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
Xue W; Ban Y; Liu H; Yao X
J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
[TBL] [Abstract][Full Text] [Related]
12. In silico screening for potent inhibitors against the NS3/4A protease of hepatitis C virus.
Meeprasert A; Rungrotmongkol T; Li MS; Hannongbua S
Curr Pharm Des; 2014; 20(21):3465-77. PubMed ID: 24001230
[TBL] [Abstract][Full Text] [Related]
13. Rational drug discovery: Ellagic acid as a potent dual-target inhibitor against hepatitis C virus genotype 3 (HCV G3) NS3 enzymes.
Lim SK; Othman R; Yusof R; Heh CH
Chem Biol Drug Des; 2021 Jan; 97(1):28-40. PubMed ID: 32657543
[TBL] [Abstract][Full Text] [Related]
14. Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure-Activity Relationships.
Hu K; Zhu Z; Mathahs MM; Tran H; Bommer J; Testa CA; Schmidt WN
Drug Des Devel Ther; 2020; 14():757-771. PubMed ID: 32158194
[TBL] [Abstract][Full Text] [Related]
15. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.
Summa V; Ludmerer SW; McCauley JA; Fandozzi C; Burlein C; Claudio G; Coleman PJ; Dimuzio JM; Ferrara M; Di Filippo M; Gates AT; Graham DJ; Harper S; Hazuda DJ; Huang Q; McHale C; Monteagudo E; Pucci V; Rowley M; Rudd MT; Soriano A; Stahlhut MW; Vacca JP; Olsen DB; Liverton NJ; Carroll SS
Antimicrob Agents Chemother; 2012 Aug; 56(8):4161-7. PubMed ID: 22615282
[TBL] [Abstract][Full Text] [Related]
16. Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.
Pillaiyar T; Namasivayam V; Manickam M
Curr Med Chem; 2016; 23(29):3404-3447. PubMed ID: 27160539
[TBL] [Abstract][Full Text] [Related]
17. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
López-Labrador FX; Moya A; Gonzàlez-Candelas F
Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
[TBL] [Abstract][Full Text] [Related]
18. Establishment of an in vitro assay system for screening hepatitis C virus protease inhibitors using high performance liquid chromatography.
Sudo K; Inoue H; Shimizu Y; Yamaji K; Konno K; Shigeta S; Kaneko T; Yokota T; Shimotohno K
Antiviral Res; 1996 Aug; 32(1):9-18. PubMed ID: 8863991
[TBL] [Abstract][Full Text] [Related]
19. Identification of potential inhibitors for HCV NS3 genotype 4a by combining protein-ligand interaction fingerprint, 3D pharmacophore, docking, and dynamic simulation.
El-Hasab MAE; El-Bastawissy EE; El-Moselhy TF
J Biomol Struct Dyn; 2018 May; 36(7):1713-1727. PubMed ID: 28531373
[TBL] [Abstract][Full Text] [Related]
20.
Han B; Parhy B; Lu J; Hsieh D; Camus G; Martin R; Svarovskaia ES; Mo H; Dvory-Sobol H
J Clin Microbiol; 2019 Apr; 57(4):. PubMed ID: 30728196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
